| 1 | Radionuclide | Copper-64 (half-life 12.7 hours) | Gallium-68 (half-life 68 minutes) | Copper-64 (half-life 12.7 hours) |
|---|
| 2 | Chelator | SAR (next-gen ultra-stable) | HBED-CC (standard for Ga-68) | DOTAGA (modified DOTA) |
|---|
| 3 | PSMA Targeting Ligand | BisPSMA (bispecific linker design) | PSMA-11 | PSMA (similar to PSMA-11) |
|---|
| 4 | Tumor Uptake | Very high and sustained | High (but decays fast) | Moderate; drops over time |
|---|
| 5 | Off-target (Liver/Spleen) Uptake | Very low | Moderate | High (bad, due to free Cu-64) |
|---|
| 6 | Background Signal Over Time | Very low | Rising fast after 2–3 hours | Rising significantly |
|---|
| 7 | Stability In Vivo | Excellent (Cu-64 tightly locked) | Good (Ga-68 OK for few hours) | Moderate (Cu-64 leaks out) |
|---|
| 8 | Imaging Window | Up to 48 hours | Best at 1–2 hours | Limited; background increases quickly |
|---|
| 9 | Production | Requires cyclotron | Generator-based (easy, cheap) | Cyclotron required |
|---|
| 10 | Shelf Life | Long (Cu-64 12.7h) | Short (~4–6 hours) | Long (12.7h) |
|---|
| 11 | Regulatory Status | Late-stage clinical trials | Fully FDA-approved (Illuccix) | Preclinical/research use |
|---|
| 12 | Strategic Use | Deep imaging + therapy matching | Fast imaging, high-volume use | Academic studies mainly |
|---|
| 13 | Theranostic Potential | High (can pair with Cu-67) | Low (Ga-68 purely diagnostic) | Possible but inferior stability |
|---|
(20min delay)